SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities.
Emily E JohnstonIsaac MartinezElizabeth S DavisCaroline CaudillJoshua S RichmanJulienne BrackettDavid S DickensAlissa KahnCarla SchwalmArchana SharmaPratik A PatelSmita BhatiaJennifer M LevineJulie Anna Wolfsonnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
These findings provide critical information for decision making among pediatric oncologists, including inpatient versus outpatient management, cancer therapy modifications, consideration of monoclonal antibody therapy, and counseling families on infection risks in the setting of the SARS-CoV-2 pandemic. The over-representation of Hispanic and publicly insured patients in this national cohort suggests disparities that require attention.
Keyphrases
- sars cov
- monoclonal antibody
- childhood cancer
- cancer therapy
- respiratory syndrome coronavirus
- decision making
- end stage renal disease
- ejection fraction
- newly diagnosed
- young adults
- coronavirus disease
- chronic kidney disease
- prognostic factors
- stem cells
- mental health
- palliative care
- quality improvement
- patient reported outcomes
- mesenchymal stem cells
- healthcare
- african american
- affordable care act
- human health
- advanced cancer
- hiv infected
- neural network
- hiv testing